PMHNP Certification Exam (AANP/ANCC) | 2026/2027
PMHNP CERTIFICATION EXAM (AANP/ANCC)
2026/2027 | 175 Questions | Graded A+ | 100% Verified
Psychiatric-Mental Health Nurse Practitioner Certification | Expert-Aligned Structure | Exam-Ready
Instructions: Select the best answer for each question. Correct answers appear in bold cyan.
Each question is followed by a rationale explaining the clinical reasoning, practice guideline
adherence, and why alternative options are less appropriate. This exam aligns with current
AANP/ANCC PMHNP test blueprints and national practice standards.
DOMAIN 1: ADVANCED PSYCHOPHARMACOLOGY (Q1–Q30)
1. A PMHNP is treating a patient with major depressive disorder who has failed trials of two
SSRIs. The PMHNP considers switching to which medication that works via NMDA receptor
antagonism?
A) Bupropion
B) Mirtazapine
C) Esketamine (Spravato)
D) Trazodone
Correct Answer: C) Esketamine (Spravato)
Rationale: Esketamine is an NMDA receptor antagonist FDA-approved for treatment-resistant
depression, administered intranasally in a certified healthcare setting due to risk of sedation and
dissociation.
2. A patient on lithium carbonate presents with coarse tremor, ataxia, persistent vomiting, and
confusion. Serum lithium level is 2.0 mEq/L. The PMHNP should:
A) Continue lithium at a reduced dose
B) Hold lithium and provide supportive care including IV hydration
C) Add a tremor medication
D) Switch to valproic acid
Correct Answer: B) Hold lithium and provide supportive care including IV hydration
Rationale: Lithium levels >1.5 mEq/L indicate toxicity. Treatment includes immediately holding lithium,
IV hydration, and potentially hemodialysis for severe cases.
3. Which antipsychotic requires REMS program enrollment with mandatory CBC monitoring
due to risk of agranulocytosis?
A) Haloperidol
B) Olanzapine
C) Clozapine
D) Aripiprazole
Correct Answer: C) Clozapine
Rationale: Clozapine carries a 1–2% risk of agranulocytosis. The Clozapine REMS Program requires
baseline and ongoing CBC monitoring.
4. A PMHNP initiates fluoxetine for a patient also taking tramadol. The PMHNP should
monitor for which serious condition?
A) Neuroleptic malignant syndrome
B) Serotonin syndrome
C) Lithium toxicity
D) Extrapyramidal symptoms
Correct Answer: B) Serotonin syndrome
Page 1
, PMHNP Certification Exam (AANP/ANCC) | 2026/2027
Rationale: Both fluoxetine (SSRI) and tramadol (which inhibits serotonin reuptake) increase
serotonergic activity, creating risk for serotonin syndrome characterized by agitation, hyperthermia,
rigidity, and autonomic instability.
5. A patient with bipolar I disorder is maintained on valproic acid. Which lab monitoring is
essential?
A) Monthly CBC only
B) Hepatic function panels and valproic acid serum levels
C) Quarterly ECGs
D) Monthly renal function only
Correct Answer: B) Hepatic function panels and valproic acid serum levels
Rationale: Valproic acid requires monitoring of hepatic function (risk of hepatotoxicity, especially in
children), serum drug levels (therapeutic range 50–125 mcg/mL), and CBC for thrombocytopenia.
6. A patient on risperidone develops gynecomastia and galactorrhea. This adverse effect is
caused by:
A) Dopamine D1 antagonism
B) Dopamine D2 antagonism leading to hyperprolactinemia
C) Serotonin 5-HT2A antagonism
D) Muscarinic antagonism
Correct Answer: B) Dopamine D2 antagonism leading to hyperprolactinemia
Rationale: Risperidone has high affinity for D2 receptors in the tuberoinfundibular pathway. D2
antagonism disinhibits prolactin release, causing hyperprolactinemia with gynecomastia, galactorrhea,
and sexual dysfunction.
7. Which medication is FDA-approved for tardive dyskinesia associated with antipsychotic
use?
A) Benztropine
B) Propranolol
C) Valbenazine
D) Amantadine
Correct Answer: C) Valbenazine
Rationale: Valbenazine (Ingrezza) and deutetrabenazine (Austedo) are FDA-approved VMAT2 inhibitors
specifically for treatment of tardive dyskinesia.
8. A PMHNP is prescribing bupropion for a patient with MDD. Which patient history is a
contraindication?
A) Hypothyroidism
B) Seizure disorder
C) Type 2 diabetes
D) Hypertension
Correct Answer: B) Seizure disorder
Rationale: Bupropion lowers the seizure threshold and is contraindicated in patients with a history of
seizures, eating disorders, or concurrent MAOI use.
9. A pregnant patient with bipolar disorder asks about medication safety. Which mood
stabilizer carries the highest risk of neural tube defects?
A) Lithium
B) Lamotrigine
C) Valproic acid
D) Carbamazepine
Correct Answer: C) Valproic acid
Rationale: Valproic acid carries a 5–10% risk of neural tube defects and is contraindicated in
pregnancy. It should be avoided, and folate supplementation is essential for women of childbearing age
on valproate.
Page 2
, PMHNP Certification Exam (AANP/ANCC) | 2026/2027
10. A patient taking an SSRI reports new-onset bruising and bleeding gums. The PMHNP
recognizes this as:
A) Normal SSRI side effects
B) Possible serotonin-related platelet dysfunction
C) Allergic reaction
D) Vitamin K deficiency
Correct Answer: B) Possible serotonin-related platelet dysfunction
Rationale: SSRIs inhibit serotonin uptake into platelets, impairing platelet aggregation and increasing
bleeding risk. Patients should be monitored for bruising, GI bleeding, and advised about NSAID
interactions.
11. A patient taking paroxetine for depression is prescribed codeine for chronic pain. The
PMHNP should recognize that this combination may result in:
A) Reduced analgesic effect of codeine due to CYP2D6 inhibition
B) Increased risk of lithium toxicity
C) Decreased paroxetine blood levels
D) Enhanced GABAergic activity
Correct Answer: A) Reduced analgesic effect of codeine due to CYP2D6 inhibition
Rationale: Paroxetine is a strong CYP2D6 inhibitor. Codeine is a prodrug that requires CYP2D6 for
conversion to morphine. Inhibition of this enzyme reduces the analgesic efficacy of codeine.
12. A PMHNP is considering a long-acting injectable antipsychotic for a patient with
schizophrenia who struggles with medication adherence. Which agent requires loading doses
on day 1 and day 8 during initiation?
A) Aripiprazole lauroxil
B) Paliperidone palmitate
C) Olanzapine pamoate
D) Haloperidol decanoate
Correct Answer: B) Paliperidone palmitate
Rationale: Paliperidone palmitate (Invega Sustenna) requires a loading dose regimen with injections on
day 1 (234 mg) and day 8 (156 mg) to achieve therapeutic levels more rapidly. Aripiprazole lauroxil and
haloperidol decanoate do not require loading doses.
13. A patient with MDD has partial response to an SSRI at an adequate dose for 8 weeks. The
PMHNP recommends augmentation with which atypical antipsychotic that is FDA-approved
as adjunctive therapy for MDD?
A) Brexpiprazole
B) Risperidone
C) Quetiapine
D) Chlorpromazine
Correct Answer: A) Brexpiprazole
Rationale: Brexpiprazole (Rexulti) and aripiprazole (Abilify) are FDA-approved as adjunctive treatments
for MDD when there is an inadequate response to antidepressant therapy. They act as partial dopamine
D2 and serotonin 5-HT1A agonists.
14. A PMHNP prescribes lamotrigine for bipolar depression. What titration strategy is critical
to reduce the risk of Stevens-Johnson syndrome (SJS)?
A) Rapid titration to therapeutic dose within 1 week
B) Start at full therapeutic dose with CBC monitoring
C) Slow titration over several weeks, especially when co-administered with valproate
D) Begin at high dose and reduce if rash develops
Correct Answer: C) Slow titration over several weeks, especially when co-administered with
valproate
Page 3
, PMHNP Certification Exam (AANP/ANCC) | 2026/2027
Rationale: Lamotrigine requires slow titration (starting at 25 mg/day) due to risk of serious skin
reactions including SJS and toxic epidermal necrolysis. Risk is increased with valproate co-
administration, which inhibits lamotrigine metabolism, requiring an even slower titration.
15. A patient on carbamazepine for bipolar disorder reports decreased effectiveness of their
oral contraceptive. This is explained by carbamazepine's effect as a:
A) CYP3A4 and CYP1A2 enzyme inhibitor
B) Monoamine oxidase inhibitor
C) Strong CYP450 enzyme inducer reducing hormone levels
D) Selective serotonin reuptake inhibitor
Correct Answer: C) Strong CYP450 enzyme inducer reducing hormone levels
Rationale: Carbamazepine is a potent inducer of CYP3A4 and other CYP450 enzymes, increasing the
metabolism of oral contraceptives and reducing their effectiveness. Patients should be counseled to use
alternative or additional contraceptive methods.
16. A PMHNP is treating generalized anxiety disorder (GAD). Which medication has a
delayed onset of 2–4 weeks and does not cause sedation or dependence?
A) Clonazepam
B) Alprazolam
C) Buspirone
D) Lorazepam
Correct Answer: C) Buspirone
Rationale: Buspirone is a 5-HT1A partial agonist used for GAD with an onset of 2–4 weeks. Unlike
benzodiazepines, it lacks sedative effects, has no abuse potential, and does not cause physiological
dependence or withdrawal.
17. A 32-year-old patient with ADHD requests a non-stimulant medication due to a history of
substance use. The PMHNP prescribes:
A) Methylphenidate
B) Dextroamphetamine
C) Atomoxetine
D) Lisdexamfetamine
Correct Answer: C) Atomoxetine
Rationale: Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor FDA-approved for
ADHD. It is a non-stimulant with no abuse potential, making it appropriate for patients with comorbid
substance use disorders.
18. Which statement correctly differentiates clonazepam from alprazolam?
A) Clonazepam has a shorter half-life than alprazolam
B) Alprazolam has a longer half-life and is preferred for long-term use
C) Clonazepam has a longer half-life (18–50 hours) providing more stable anxiolysis
with less interdose rebound
D) Both have identical pharmacokinetic profiles
Correct Answer: C) Clonazepam has a longer half-life (18–50 hours) providing more stable
anxiolysis with less interdose rebound
Rationale: Clonazepam has a longer half-life (18–50 hours) compared to alprazolam (6–12 hours),
providing more sustained anxiolysis with less risk of interdose withdrawal and rebound anxiety. This
makes clonazepam preferable for longer-term management.
19. A patient on quetiapine develops significant weight gain, elevated fasting glucose of 180
mg/dL, and hyperlipidemia. These effects are classified as:
A) Extrapyramidal symptoms
B) Metabolic syndrome
C) Serotonin syndrome
D) Neuroleptic malignant syndrome
Page 4
PMHNP CERTIFICATION EXAM (AANP/ANCC)
2026/2027 | 175 Questions | Graded A+ | 100% Verified
Psychiatric-Mental Health Nurse Practitioner Certification | Expert-Aligned Structure | Exam-Ready
Instructions: Select the best answer for each question. Correct answers appear in bold cyan.
Each question is followed by a rationale explaining the clinical reasoning, practice guideline
adherence, and why alternative options are less appropriate. This exam aligns with current
AANP/ANCC PMHNP test blueprints and national practice standards.
DOMAIN 1: ADVANCED PSYCHOPHARMACOLOGY (Q1–Q30)
1. A PMHNP is treating a patient with major depressive disorder who has failed trials of two
SSRIs. The PMHNP considers switching to which medication that works via NMDA receptor
antagonism?
A) Bupropion
B) Mirtazapine
C) Esketamine (Spravato)
D) Trazodone
Correct Answer: C) Esketamine (Spravato)
Rationale: Esketamine is an NMDA receptor antagonist FDA-approved for treatment-resistant
depression, administered intranasally in a certified healthcare setting due to risk of sedation and
dissociation.
2. A patient on lithium carbonate presents with coarse tremor, ataxia, persistent vomiting, and
confusion. Serum lithium level is 2.0 mEq/L. The PMHNP should:
A) Continue lithium at a reduced dose
B) Hold lithium and provide supportive care including IV hydration
C) Add a tremor medication
D) Switch to valproic acid
Correct Answer: B) Hold lithium and provide supportive care including IV hydration
Rationale: Lithium levels >1.5 mEq/L indicate toxicity. Treatment includes immediately holding lithium,
IV hydration, and potentially hemodialysis for severe cases.
3. Which antipsychotic requires REMS program enrollment with mandatory CBC monitoring
due to risk of agranulocytosis?
A) Haloperidol
B) Olanzapine
C) Clozapine
D) Aripiprazole
Correct Answer: C) Clozapine
Rationale: Clozapine carries a 1–2% risk of agranulocytosis. The Clozapine REMS Program requires
baseline and ongoing CBC monitoring.
4. A PMHNP initiates fluoxetine for a patient also taking tramadol. The PMHNP should
monitor for which serious condition?
A) Neuroleptic malignant syndrome
B) Serotonin syndrome
C) Lithium toxicity
D) Extrapyramidal symptoms
Correct Answer: B) Serotonin syndrome
Page 1
, PMHNP Certification Exam (AANP/ANCC) | 2026/2027
Rationale: Both fluoxetine (SSRI) and tramadol (which inhibits serotonin reuptake) increase
serotonergic activity, creating risk for serotonin syndrome characterized by agitation, hyperthermia,
rigidity, and autonomic instability.
5. A patient with bipolar I disorder is maintained on valproic acid. Which lab monitoring is
essential?
A) Monthly CBC only
B) Hepatic function panels and valproic acid serum levels
C) Quarterly ECGs
D) Monthly renal function only
Correct Answer: B) Hepatic function panels and valproic acid serum levels
Rationale: Valproic acid requires monitoring of hepatic function (risk of hepatotoxicity, especially in
children), serum drug levels (therapeutic range 50–125 mcg/mL), and CBC for thrombocytopenia.
6. A patient on risperidone develops gynecomastia and galactorrhea. This adverse effect is
caused by:
A) Dopamine D1 antagonism
B) Dopamine D2 antagonism leading to hyperprolactinemia
C) Serotonin 5-HT2A antagonism
D) Muscarinic antagonism
Correct Answer: B) Dopamine D2 antagonism leading to hyperprolactinemia
Rationale: Risperidone has high affinity for D2 receptors in the tuberoinfundibular pathway. D2
antagonism disinhibits prolactin release, causing hyperprolactinemia with gynecomastia, galactorrhea,
and sexual dysfunction.
7. Which medication is FDA-approved for tardive dyskinesia associated with antipsychotic
use?
A) Benztropine
B) Propranolol
C) Valbenazine
D) Amantadine
Correct Answer: C) Valbenazine
Rationale: Valbenazine (Ingrezza) and deutetrabenazine (Austedo) are FDA-approved VMAT2 inhibitors
specifically for treatment of tardive dyskinesia.
8. A PMHNP is prescribing bupropion for a patient with MDD. Which patient history is a
contraindication?
A) Hypothyroidism
B) Seizure disorder
C) Type 2 diabetes
D) Hypertension
Correct Answer: B) Seizure disorder
Rationale: Bupropion lowers the seizure threshold and is contraindicated in patients with a history of
seizures, eating disorders, or concurrent MAOI use.
9. A pregnant patient with bipolar disorder asks about medication safety. Which mood
stabilizer carries the highest risk of neural tube defects?
A) Lithium
B) Lamotrigine
C) Valproic acid
D) Carbamazepine
Correct Answer: C) Valproic acid
Rationale: Valproic acid carries a 5–10% risk of neural tube defects and is contraindicated in
pregnancy. It should be avoided, and folate supplementation is essential for women of childbearing age
on valproate.
Page 2
, PMHNP Certification Exam (AANP/ANCC) | 2026/2027
10. A patient taking an SSRI reports new-onset bruising and bleeding gums. The PMHNP
recognizes this as:
A) Normal SSRI side effects
B) Possible serotonin-related platelet dysfunction
C) Allergic reaction
D) Vitamin K deficiency
Correct Answer: B) Possible serotonin-related platelet dysfunction
Rationale: SSRIs inhibit serotonin uptake into platelets, impairing platelet aggregation and increasing
bleeding risk. Patients should be monitored for bruising, GI bleeding, and advised about NSAID
interactions.
11. A patient taking paroxetine for depression is prescribed codeine for chronic pain. The
PMHNP should recognize that this combination may result in:
A) Reduced analgesic effect of codeine due to CYP2D6 inhibition
B) Increased risk of lithium toxicity
C) Decreased paroxetine blood levels
D) Enhanced GABAergic activity
Correct Answer: A) Reduced analgesic effect of codeine due to CYP2D6 inhibition
Rationale: Paroxetine is a strong CYP2D6 inhibitor. Codeine is a prodrug that requires CYP2D6 for
conversion to morphine. Inhibition of this enzyme reduces the analgesic efficacy of codeine.
12. A PMHNP is considering a long-acting injectable antipsychotic for a patient with
schizophrenia who struggles with medication adherence. Which agent requires loading doses
on day 1 and day 8 during initiation?
A) Aripiprazole lauroxil
B) Paliperidone palmitate
C) Olanzapine pamoate
D) Haloperidol decanoate
Correct Answer: B) Paliperidone palmitate
Rationale: Paliperidone palmitate (Invega Sustenna) requires a loading dose regimen with injections on
day 1 (234 mg) and day 8 (156 mg) to achieve therapeutic levels more rapidly. Aripiprazole lauroxil and
haloperidol decanoate do not require loading doses.
13. A patient with MDD has partial response to an SSRI at an adequate dose for 8 weeks. The
PMHNP recommends augmentation with which atypical antipsychotic that is FDA-approved
as adjunctive therapy for MDD?
A) Brexpiprazole
B) Risperidone
C) Quetiapine
D) Chlorpromazine
Correct Answer: A) Brexpiprazole
Rationale: Brexpiprazole (Rexulti) and aripiprazole (Abilify) are FDA-approved as adjunctive treatments
for MDD when there is an inadequate response to antidepressant therapy. They act as partial dopamine
D2 and serotonin 5-HT1A agonists.
14. A PMHNP prescribes lamotrigine for bipolar depression. What titration strategy is critical
to reduce the risk of Stevens-Johnson syndrome (SJS)?
A) Rapid titration to therapeutic dose within 1 week
B) Start at full therapeutic dose with CBC monitoring
C) Slow titration over several weeks, especially when co-administered with valproate
D) Begin at high dose and reduce if rash develops
Correct Answer: C) Slow titration over several weeks, especially when co-administered with
valproate
Page 3
, PMHNP Certification Exam (AANP/ANCC) | 2026/2027
Rationale: Lamotrigine requires slow titration (starting at 25 mg/day) due to risk of serious skin
reactions including SJS and toxic epidermal necrolysis. Risk is increased with valproate co-
administration, which inhibits lamotrigine metabolism, requiring an even slower titration.
15. A patient on carbamazepine for bipolar disorder reports decreased effectiveness of their
oral contraceptive. This is explained by carbamazepine's effect as a:
A) CYP3A4 and CYP1A2 enzyme inhibitor
B) Monoamine oxidase inhibitor
C) Strong CYP450 enzyme inducer reducing hormone levels
D) Selective serotonin reuptake inhibitor
Correct Answer: C) Strong CYP450 enzyme inducer reducing hormone levels
Rationale: Carbamazepine is a potent inducer of CYP3A4 and other CYP450 enzymes, increasing the
metabolism of oral contraceptives and reducing their effectiveness. Patients should be counseled to use
alternative or additional contraceptive methods.
16. A PMHNP is treating generalized anxiety disorder (GAD). Which medication has a
delayed onset of 2–4 weeks and does not cause sedation or dependence?
A) Clonazepam
B) Alprazolam
C) Buspirone
D) Lorazepam
Correct Answer: C) Buspirone
Rationale: Buspirone is a 5-HT1A partial agonist used for GAD with an onset of 2–4 weeks. Unlike
benzodiazepines, it lacks sedative effects, has no abuse potential, and does not cause physiological
dependence or withdrawal.
17. A 32-year-old patient with ADHD requests a non-stimulant medication due to a history of
substance use. The PMHNP prescribes:
A) Methylphenidate
B) Dextroamphetamine
C) Atomoxetine
D) Lisdexamfetamine
Correct Answer: C) Atomoxetine
Rationale: Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor FDA-approved for
ADHD. It is a non-stimulant with no abuse potential, making it appropriate for patients with comorbid
substance use disorders.
18. Which statement correctly differentiates clonazepam from alprazolam?
A) Clonazepam has a shorter half-life than alprazolam
B) Alprazolam has a longer half-life and is preferred for long-term use
C) Clonazepam has a longer half-life (18–50 hours) providing more stable anxiolysis
with less interdose rebound
D) Both have identical pharmacokinetic profiles
Correct Answer: C) Clonazepam has a longer half-life (18–50 hours) providing more stable
anxiolysis with less interdose rebound
Rationale: Clonazepam has a longer half-life (18–50 hours) compared to alprazolam (6–12 hours),
providing more sustained anxiolysis with less risk of interdose withdrawal and rebound anxiety. This
makes clonazepam preferable for longer-term management.
19. A patient on quetiapine develops significant weight gain, elevated fasting glucose of 180
mg/dL, and hyperlipidemia. These effects are classified as:
A) Extrapyramidal symptoms
B) Metabolic syndrome
C) Serotonin syndrome
D) Neuroleptic malignant syndrome
Page 4
